КОМБИНИРОВАННЫЕ ВАКЦИНЫ В ПРАКТИКЕ ПЕДИАТРА: КОГДА КОКЛЮШНАЯ ПРИВИВКА В РАДОСТЬ!
https://doi.org/10.15690/pf.v9i4.386
Аннотация
Об авторе
В. К. ТаточенкоРоссия
доктор медицинских наук, профессор, главный научный сотрудник НЦЗД РАМН
Список литературы
1. Cherry J. et al. A search for serologic correlates of immunity to Bordetella pertussiscoughs illnesses. Vaccine. 1998; 16: 1901–1906.
2. Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). A review of its use as primary and booster vaccination. Drugs. 2010; 70 (8): 1022–1058.
3. Zepp F., Schmitt H-J., Cleerboat J. et al. Rewiev of 8 years of experience with Infanrix hexa (DTPa — HBV-IPV/Hib hexavalent vaccine). Expert rew. Vaccine. 2009; 8 (6): 663–676.
4. Zinke M., Kappes R., Kindler K. et al. Immune memory to hepatitis B virus in 4–9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Human Vaccines. 2009; 5 (9): 592–599.
5. Pichichero M. E., Blatter M. M., Reisinger K. S. et al. Impact o f a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussishepatitis B-inactivated poliovirus — Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J. 2002; 21 (9): 854–859.
6. Fong-Seng L., Htay-Htay H., Jacquet J.-M., Bock H. L. Primary vac cination of infants against hepatitis b can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis — Haemophilus influenzae type B vaccine. Annals Academy of Medicine. 2007; 36 (10): 801–806.
7. Omenaca F., Garcia-Sicilia J., Garcia-Corbeira P. et al. Response of preterm newborns to immunization with a hexavalent diphtheriatetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemo philus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005; 116 (6): 1292–1298.
8. Kalies H., Grote V., Siedler A. et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine. 2008; 26 (20): 2545–2552.
9. Schmitt H. J., von Koеnig C. H., Neiss A. et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996; 275 (1): 37–41.
10. Greco D., Salmaso S., Mastrantonio P. et al. On behalf of the Progetto Pertosse Working Group A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996; 334 (6): 341–348.
11. Информационное Письмо Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 18 мая 2007 г. № 0100/5137-07-32 Приложение № 2 «О тактике иммунизации при удлинении интервалов между прививками против гепатита В». 12. Gimenez-Sanchez F., Kieninger D. M., Kueper K. et al. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29: 6042– 6048.
12. Vanden Bergh M. R., Spijkerman J., Francois N. et al. Immunogenicity, safety, and reactogenicity of the 10-valen tpneumococca lnontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccinations chedule in the Netherlands. A randomized controlled trial. Pediatr Infect Dis J. 2011; 30: 170–178.
13. Tejedor J., Omenaca F., Garcia-Sicilia J. et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004; 23 (12): 1109–1115.
14. Knuf M., Pantazi-Chatzikonstantinou A., Pfletschinger U. et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanustoxoidconjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children. Vaccine. 2011; 29: 4264–4273.
15. Tejedor J. C., Garcia-Sicilia J., Grunert D. et al. Co-administration of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHID-CV) with other routine paediatric vaccines. 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD-6). Reykjavik, Iceland. 8–12 June 2008.
16. ВОЗ, ЮНИСЕФ, Всемирный Банк. Положение в мире относительно вакцин и иммунизации. 3-е издание. ВОЗ, Женева. 2009.
17. Hviid A., Wohlfahrt J., Stellfeld V., Melbyt M. Childhood vaccination and nontargeted infectious disease hospitalization. JAMA. 2005; 294 (6): 699–705.
Рецензия
Для цитирования:
Таточенко В.К. КОМБИНИРОВАННЫЕ ВАКЦИНЫ В ПРАКТИКЕ ПЕДИАТРА: КОГДА КОКЛЮШНАЯ ПРИВИВКА В РАДОСТЬ! Педиатрическая фармакология. 2012;9(4):26-31. https://doi.org/10.15690/pf.v9i4.386
For citation:
Tatochenko V.K. COMBINED VACCINES IN PEDIATRIC PRACTICE: WHEN THE PERTUSSIS VACCINE IS FUN! Pediatric pharmacology. 2012;9(4):26-31. (In Russ.) https://doi.org/10.15690/pf.v9i4.386